Normal tension glaucoma patients
Conditions
Interventions
Four-week intake of the test food product
Sponsors
HUMA R&D CORP
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Males and females with Japanese nationality aged 40 and over 2) Diagnosed with normal tension glaucoma 3) Persons who can bring their glaucoma medication on study days 4) Low in biological antioxidant potential (BAP) and high in oxidative stress (8-OHdG) in urine
Exclusion criteria
Exclusion criteria: "1) Presence of severe ophthalmic disorder and regular visit to an ophthalmic clinic 2) High myopia 3) Within three months after eye surgery 4) Previous history of the LASIK procedure 5) Presence of disorder with a possible influence on study results (cancer, high-blood pressure, diabetes, amblyopia, autoimmune disorder, dysthyroidism, etc.) 6) Intake of a food product (antioxidant supplements other than vitamin C, etc.) with a possible influence on the study results at a frequency of once a week or more within the last month, or desired to take the food product at the frequency of once a week or more 7) Previous history of drug allergy or food allergy, possible onset of allergy by the study 8) Currently in treatment with medication that regulates blood pressure or blood flow 9) Presence of disorder that requires constant medication, or previous history of severe disorder that required treatment with medication 10) Regular intake of another supplement or non-prescription drug (including ophthalmic drops for purposes other than glaucoma treatment of glaucoma) 11) Persons whose results of clinical and physical examination prior to intake of the test food product significantly deviate from reference ranges 12) Current participation in another clinical study or participation in another clinical study within the last month since acquisition of the consent 13) Pregnant or desired to become pregnant and nurse during the study period 14) Determined to be unsuitable as subjects from results of the lifestyle survey 15) Determined by the investigator to be unsuitable for enrollment in this study "
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 8-OHdG | — |
Countries
Japan
Contacts
Public Contactochitani daisuke
HUMA R&D CORP Clinical Development Division
Outcome results
None listed